Sign up to save your podcasts
Or
Share The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immune response against NHL.
This podcast features experts Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, who discusses the future of CAR-T therapy and the risk of secondary malignancies, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who gives an overview of the currently approved CAR-T products and bispecific antibodies in large B-cell lymphoma, and the optimal sequencing of these agents.
The post The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies appeared first on VJHemOnc.
View all episodes
By VJHemOnc
4.5
22 ratings
Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immune response against NHL.
This podcast features experts Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, who discusses the future of CAR-T therapy and the risk of secondary malignancies, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who gives an overview of the currently approved CAR-T products and bispecific antibodies in large B-cell lymphoma, and the optimal sequencing of these agents.
The post The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies appeared first on VJHemOnc.
More shows like VJHemOnc Podcast
View all
Hematologic Oncology Update
76 Listeners
Mayo Clinic Talks
289 Listeners
The Curbsiders Internal Medicine Podcast
3,341 Listeners
Blood Podcast
53 Listeners
CCO Oncology Podcast
9 Listeners
Blood Cancer Talks
49 Listeners
Two Onc Docs
185 Listeners
All Things Amyloid
5 Listeners
The Hematology Podcast Series!
0 Listeners